Wed, May 2, 2012
[ Wed, May 02nd 2012 ]: Market Wire
Location Change
Tue, May 1, 2012
Mon, April 30, 2012
[ Mon, Apr 30th 2012 ]: Market Wire
Hologic to Acquire Gen-Probe
Sun, April 29, 2012
Sat, April 28, 2012
Fri, April 27, 2012
Thu, April 26, 2012
Wed, April 25, 2012
Tue, April 24, 2012
Mon, April 23, 2012
Sun, April 22, 2012
Sat, April 21, 2012
Fri, April 20, 2012
Thu, April 19, 2012

Simcere Pharmaceutical Group Filed 2011 Annual Report on Form 20-F

  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. group-filed-2011-annual-report-on-form-20-f.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

- Click to Lock Slider

Simcere Pharmaceutical Group Filed 2011 Annual Report on Form 20-F -- NANJING, China, April 26, 2012 /PRNewswire-Asia/ --

Simcere Pharmaceutical Group Filed 2011 Annual Report on Form 20-F

[ ]

NANJING, China, April 26, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: [ SCR ]), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, announced today that the Company filed its annual report on Form 20-F for the year ended December 31, 2011 with the Securities and Exchange Commission on April 25, 2012, U.S. Eastern Time. The annual report can be accessed on the Company's investor relations website at [ http://ir.simcere.com ]. The Company will provide a hard copy of the annual report containing its audited financial statements for the year ended December 31, 2011, free of charge, to its shareholders and ADS holders upon request.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group ("Simcere") (NYSE: [ SCR ]) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit [ www.simcere.com ].

Investor and Media Contacts:

Email: [ ir@simcere.com ]




In Nanjing:

In the United States:

Yehong Zhang

Cindy Zheng

President

Brunswick Group

Simcere Pharmaceutical Group

Tel: 1-212-333-3810

Tel: 86-25-8556-6666 ext. 8811




In Beijing:

In Hong Kong:

Yue Yu

Joseph Lo Chi-Lun

Brunswick Group

Brunswick Group

Tel: 86-10-5960-8600

Tel: 852-3512-5000



SOURCE Simcere Pharmaceutical Group

[ Back to top ]

RELATED LINKS
[ http://www.simcere.com ]
[ http://ir.simcere.com ]